### Data supplement for

# Genetic heterogeneity and subtypes of major depression

Thuy-Dung Nguyen<sup>1,2</sup>; Arvid Harder<sup>1</sup>; Ying Xiong<sup>1</sup>; Kaarina Kowalec<sup>1,3</sup>; Sara Hägg<sup>1</sup>; Na Cai<sup>4</sup>, Ralf Kuja-Halkola<sup>1</sup>; Christina Dalman<sup>2</sup>; Patrick F Sullivan<sup>1,5</sup>; Yi Lu<sup>1,2</sup>

- 1. Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden
- 2. Department of Global Public Health, Karolinska Institute, Stockholm, Sweden
- 3. College of Pharmacy, University of Manitoba, Winnipeg, Canada
- 4. Helmholtz Pioneer Campus, Helmholtz Zentrum München, Neuherberg, Germany
- 5. Department of Genetics and Psychiatry, University of North Carolina, Chapel Hill, NC, USA

#### **Table of Contents**

I.	SUPPLEMENTARY METHODS	2
	S1.1 Materials UKB cohort	
	MD case definitions MD subtypes	
	S1.2 Statistical analysis Genome-wide association studies (GWAS) SNP-Heritability Genetic correlation Sensitivity analyses	3 4 4
11.	SUPPLEMENTARY TABLES	6
	Table S1 Summary of current literature on MD subtype heterogeneity	.6
	Table S2 Method to derive of MD cases, control and exclusion criteria in UKB	.7
	Table S3 MD definitions and derived subtypes1	1
	Table S4 Method to derive MD subtypes in UKB data         1	L <b>2</b>
	Table S5 Medication list         1	5ا
	Table S6 Prevalence of subtypes to convert $h_g^2$ from observed to liability scale	L <b>7</b>
	Table S7 Significant loci in MD subtypes and broad MD phenotype GWAS	19
	Table S8 SNP-heritability and genetic correlation for subtypes within CIDI-SF MD cases	24
	Table S9 Compare subtype $h^2$ between primary analysis and independent controls analysis 2	25
	SUPPLEMENTARY FIGURES2	?6
	Figure S1 Included sample of study2	26
	Figure S2 SNP- heritability for MD definitions in UKB2	27
	Figure S3 SNP-heritability on liability scale using different conversion methods2	28
	Figure S4 Subtype SNP-heritability estimated among all samples and unrelated samples2	<u>29</u>
	Figure S5 Phenotypic and genetic correlation across MD subtypes3	30
R	EFERENCES	31

### I. SUPPLEMENTARY METHODS

### S1.1 Materials

### **UKB** cohort

All UKB participants were invited to one of the assessment centers and answered touchscreen questionnaires that contains a section about mental health, followed by an interview with a research nurse where more details about mental illness and medication use were obtained. Psychiatric disorders diagnosed by clinicians were obtained from hospital admission records. Additionally, ~158,000 participants completed a web-based mental health questionnaire (MHQ) which is based on the Composite International Diagnostic Interview (CIDI).

### **MD** case definitions

The broad MD phenotype in this study is a composition of five MD definitions, including:

- (1) Lifetime depression based on the CIDI Short Form, i.e., lifetime depression according to the DSM-V criteria;
- (2) ICD-coded depression, i.e., any primary or secondary clinical diagnosis of major depressive disorder from linked hospital admission records;
- (3) Probable MD, i.e., presence of low mood or anhedonia for  $\geq 2$  weeks and 'help-seeking';
- (4) Self-reported MD, i.e., those self-reported having MD during nurse interview or mental health problems ever diagnosed by a professional as part of MHQ;
- (5) MD cardinal symptoms, i.e., ever had prolonged loss of interest in normal activities; or prolonged feelings of sadness or depression.

See Supplementary table S2 about how to derive the MD definitions from UKB data.

### **MD** subtypes

See Supplementary table S4 for methods to derive MD subtypes in UKB data.

<u>MD with atypical-like features versus non-atypical-like features.</u> Symptoms of MD were extracted from the MHQ online follow-up, and used to determine if the participant had atypical-like features versus without atypical-like features. As in a previous study<sup>1, 2</sup>, we defined MD with atypical-like features subtype as MD cases who reported both hypersomnia (UKB field: 20534) and weight gain (UKB field: 20536), and the others were non-atypical-like features MD subtype. This definition should be considered separately from the 'atypical MD', which requires the endorsement of full DSM criteria including mood reactivity and other atypical symptoms.

<u>Severe versus mild/moderate MD</u>. The subtypes on symptom severity compared the cases with mild/moderate versus severe symptoms. Mild/moderate MD included those with probable recurrent MD (moderate) defined by Smith et al.<sup>3</sup> (UKB field: 20126), and/or ICD-diagnoses of mild (F320, F330) or moderate depression episode (F321, F331) (UKB field: 41202, 41204). Severe MD included probable recurrent MD (severe) defined by Smith et al.<sup>3</sup> (UKB field: 20126); and/or ICD-diagnoses of severe MD (F322, F323, F332, F333) (UKB field: 41202, 41204).

<u>MD with or without comorbid anxiety disorder.</u> The MD subtypes with or without comorbid anxiety disorder were defined using both self-reported and ICD-coded diagnoses. Participants of the MHQ reported mental health problems diagnosed by a professional (UKB 20544). Among the MD cases, we defined the subtype with comorbid anxiety disorder as those who also reported social anxiety/phobia, panic attacks, and anxiety, nerves/generalized anxiety disorder in the MHQ, and/or those with ICD diagnoses (UKB field: 41202, 41204) of anxiety disorder (F40, F41). For comparison, MD without comorbid anxiety disorder included MD cases with neither self-reported nor ICD-codes anxiety disorder.

<u>Early versus late onset MD.</u> Among >89,000 participants who answered the MHQ online follow-up, those who had MD cardinal symptoms reported the age at which they first experienced a  $\geq$ 2-week episode (UKB field: 20433). Similar to previous studies<sup>4, 5</sup>, we categorized the continuous variable of age at onset into octiles, then grouped the first 3 octiles into early-onset subtype (age onset  $\leq$ 30) and the last 3 octiles into late-onset subtype (age onset  $\geq$ 44).

<u>Recurrent versus single-episode MD.</u> Recurrent MD subtype was defined as those with probable recurrent MD defined by Smith et al.  $(2013)^3$  (UKB field: 20126), and/or with  $\geq 2$  episodes of at least two weeks of cardinal symptoms (UKB field: 20442)<sup>6</sup>, and/or ICD-diagnosis of recurrent MD (F33). Single-episode subtype included probable MD cases with one episode of feeling depressed (UKB field: 20126), and/or those self-reported a single episode (UKB field: 20442)<sup>6</sup>, and/or ICD-diagnosis of non-recurrent MD (F32).

<u>MD with or without suicidality.</u> The subtype MD with suicidal thoughts included those who had reported thoughts of death during worst depression (UKB field: 20437); and/or those with recent thoughts of suicide or self-harm (UKB field: 20513). Non-suicidal subtype included MD cases who did not report suicidal thoughts.

<u>MD with mild, moderate, severe impairment.</u> Individuals who reported cardinal symptoms of MD were asked about the impact of MD on normal roles, including study/employment, childcare and housework, leisure pursuits, during the worst period of depression (UKB field: 20440). We categorized 'not at all/a little impact' as mild impairment, 'somewhat' as moderate impairment and 'a lot' as severe impairment.

<u>Postpartum depression (PPD)</u> cases were identified from three sources: women who reported postnatal depression during the nurse interview at the baseline recruitment (UKB field: 20002, code 1531); cases with MD cardinal symptoms related to childbirth (UKB field: 20445); and women with ICD diagnosis of mental and behavioral disorders associated with the puerperium (F53 in UKB fields: 41202, 41204).

## S1.2 Statistical analysis

### Genome-wide association studies (GWAS)

For GWAS, we constructed a genetic relationship matrix (GRM) for all UKB individuals of European ancestries based on 575,805 LD-pruned HapMap3 variants (LD-pruning parameters in PLINK 1.9: window size = 1Mb, step size = 100, r<sup>2</sup> = 0.9). From a full GRM, we derived a sparse GRM by setting all elements <0.05 to 0 (--grm-sparse flag in GCTA). We then conducted case-control GWAS for each subtype using fastGWA<sup>2</sup>, adjusting for sex, age, and the first 10 PCs. Summary statistics were available for ~9.7 million common variants in each GWAS after filtering out those with low imputation quality (INFO<0.6). Compared to other methods, fastGWA has efficiency as the advantage. Since we have a large sample size and 30% of the sample is related, using fastGWA is more computationally efficient and help maximizing power by retaining related individuals. Simulation showed that results obtained from fastGWA was nearly identical to that from other methods like REML algorithm implemented in GCTA22 or test statistic computed using the GRAMMAR-GAMMA approximation.<sup>2</sup>

For annotation in FUMA<sup>7</sup>, we applied the following parameters for lead SNPs: maximum P-value of lead SNPs < 5e-8, r2 threshold to define independent significant SNPs >=0.6, 2nd r2 threshold to define lead SNPs >=0.1, maximum distance between LD blocks to merge into a locus <250kb, with 1000G Phase3 European ancestry as reference panel. The mapped genes are based on positional and expression quantitative trait loci (eQTL).

### **SNP-Heritability**

We used linkage disequilibrium score regression  $(LDSC)^8$  to estimate SNP-heritability  $(h^2_{SNP})$  on observed scale based on 50:50 case-control ascertainment<sup>9</sup> for each MD subtype. LDSC estimates SNP-heritability by regressing GWAS summary statistics on LD scores estimated from a reference population. We used LD scores from the European samples in the 1000 genomes reference panel. For each subtype, we calculated N effective using the formula N\_effective =4\*p\*(1-p)\*N, with sample case proportion p and total sample size N.

For comparison, we estimated heritability on observed scale (not specifying N\_case/N\_control in LDSC software), then converted into liability scale using two methods. First, we converted  $h^2_{SNP}$  from the observed to the liability scale based on the standard conversion from Lee et al (2011)<sup>10</sup> (Equation 23), which takes into account sample prevalence and population prevalence. Second, we corrected for oversampling and extreme phenotype selection using sample prevalence, population case and control prevalence based on Yap et al. (2018) - formula 1- *Supplementary method*<sup>11</sup>. The main *Figure 1b* presents  $h^2_{SNP}$  on liability scale with a range of population case prevalence for each subtype based on Yap et al. (2018). Results from the 3 methods are presented in *Supplementary table S6* and *figure S3*.

We confirmed significant differences in  $h_{SNP}^2$  estimates within subtype comparisons by splitting controls into 2 or 3 random subsets. Each control subset was combined with subtype cases for GWAS and estimating  $h_{SNP}^2$  (Supplementary table S9).

To ensure that the potential disproportionate power gain across subtype by modelling relatedness in fastGWA did not affect our heritability comparisons, we also estimated  $h^{2}_{SNP}$  based on unrelated samples. After removing all genetic-inferred related individuals<sup>12</sup>, we conducted GWAS using logistic regression in Plink, then estimated  $h^{2}_{SNP}$  using LDSC. (*Supplementary Figure S4*).

### **Genetic correlation**

Genetic correlations ( $r_g$ ) were estimated using a recent extension of LDSC, High-Definition Likelihood (HDL) method.<sup>13</sup> Similar principle as in estimating heritability, the genetic correlation between two traits is estimated by contrasting the covariance matrix of z-scores 1 (trait 1)-z-scores 2 (trait 2) and the LD scores matrix.<sup>14</sup> HDL exploits all elements of the z-scores covariance matrix instead of just the diagonal elements as in LDSC, and thus yields more precise estimates of genetic correlations compared to LDSC.<sup>13</sup> We estimated genetic correlations within subtype comparisons, using the LD reference computed from 336 000 Genomic British individuals in the UKB.

For the primary analysis, we estimated genetic correlation for each pair of subgroups within a comparison group. GWAS summary statistics data were processed into the right format with z-scores by HDL.data.wrangling.R function in HDL program (https://github.com/zhenin/HDL/wiki/Format-of-summary-statistics). LD reference panel used is the eigenvalues and eigenvectors of LD matrices for the European-ancestry population. The matrices were computed from 335,265 Genomic British individuals in UK Biobank (https://github.com/zhenin/HDL/wiki/Reference-panels). Details about the HDL program could be found at <a href="https://github.com/zhenin/HDL/wiki.">https://github.com/zhenin/HDL/wiki/Reference-panels</a>). Details about the HDL program could be found at <a href="https://github.com/zhenin/HDL/wiki">https://github.com/zhenin/HDL/wiki</a>

### Sensitivity analyses

It has been argued that results relying on minimal phenotyping (*i.e.*, the definitions of MD are not strictly based on structured clinical interviews, but instead rely on a few self-reported answers) may bias views of genetic architecture of MD.<sup>6</sup> To examine whether our broad MD definition may bias the results, we further restricted the analyses to the CIDI-based definition—previously suggested as the closest to the gold standard for diagnosing MD in the UKB<sup>6, 15</sup>—and estimated  $h^2_{SNP}$  and genetic

correlations for all subtypes except impairment because moderate to severe impairment is part of the CIDI-based MD criteria.

Cases of subtypes were defined using the same criteria as primary analyses, then we only included people who also met criteria for CIDI-based MD (*Supplementary table S4*). Control group was the same as in the primary GWAS analyses. We estimated  $h^2_{SNP}$  on the observed scale based on 50:50 case-control ascertainment<sup>9</sup>, and on liability scale using conversion in Yap et al. (2018)<sup>11</sup> (*Supplementary table S6*). Estimates of  $h^2_{SNP}$  and  $r_g$  are presented in *Supplementary table S8*.

In the primary analyses, we considered that subtype heritability within the same comparison group are significantly different when non-overlapping confidence intervals are presented, we performed statistical tests to confirm significance for the three subtype categories with non-overlapped CI from the original results (age at onset, suicidality, and impairment). We split the control group into 2 random subsets, each subtype in the same category consisted of one control subset. We conducted GWAS using fastGWA and estimated heritability with LDSC. Results are presented in *Supplementary table S9*.

#### II. SUPPLEMENTARY TABLES

#### Table S1 Summary of current literature on MD subtype heterogeneity

Culatura e			Her	itability		Genetic overlap	Culatura anasifia
Subtype category	Clinical features <sup>+</sup>	Comparisons <sup>†</sup>	h²	h² <sub>SNP</sub>	<i>r<sub>g</sub></i> within comparison	Overlap w other traits (PRS/ $r_g$ )	Subtype specific GWAS
	Vegetative symptom	Atypical Typical		Null <sup>++16-18</sup> Null <sup>++16-18</sup>		PRS of metabolic traits more associated with atypical MD <sup>16, 17</sup> $r_g$ atypical w. BMI= 0.53 (95% CI= 0.23-0.82) <sup>18</sup>	
Symptom- based	Symptom soverity	Severe Mild/ moderate		ivun		<i>r<sub>g</sub></i> typical w. BMI= −0.28 (95% CI=−0.55;−0.01) <sup>18</sup>	
	Comorbid anxiety disorder	With anxiety Without anxiety					
Time of	Age at onset		0.21(0.12-0.28) <sup>19</sup> 0.23(0.13-0.32) <sup>19</sup>			Stronger PRS association between early-onset MDD with BIP/SCZ <sup>4</sup>	1 locus <sup>4</sup>
onset/course	Recurrence	Single Recurrent	0.28(0.14-0.41) <sup>19</sup> 0.41(0.2-0.6) <sup>19</sup>		0.86 (0.68-0.97) <sup>19</sup>		2 loci in Han Chinese <sup>20</sup>
Treatment- related &	Suicidality	w suicidal thoughts w/o suicidal thoughts					
other outcomes	Impairment	Mild Moderate Severe					
	PPD	PPD	0.44(0.35-0.52) <sup>21</sup>				
Etiologically- based	Environment	With trauma/ adversity		Inconsistent <sup>+++22, 23</sup>	0.77 (0.48-1.05) <sup>22</sup>	Stronger association between MD w trauma and body composition, socioeconomic <sup>22</sup>	Not found <sup>23</sup>
Juseu		Without trauma/ adversity		Inconsistent <sup>+++22, 23</sup>	0.64 (0.19-1.09) <sup>23</sup>		3 loci in Han Chinese <sup>23</sup>
Gender-based	Sex		$0.44(0.25-0.61)^{19}$ $0.35(0.08-0.63)^{19}$		0.89 (0.87-0.91) <sup>25</sup>		Not found <sup>24</sup> 1 locus <sup>24</sup>

*MD: major depression. PPD: postpartum depression. BIP: Bipolar disorder. SCZ: Schizophrenia.*  $h^2$ : heritability.  $h^2_{SNP}$ : SNP-heritability.  $r_g$ : Genetic correlation. PRS: Polygenic Risk Score

\*The subtypes examined in this study were highlighted in bold. Subtypes with or without trauma were not studied here because similar analyses using the UK biobank were available; and sex-specific subtypes were not studied because it has been heavily studied and evidence were convincing.

<sup>++</sup> Compared with MD with typical symptoms,  $h^2_g$  estimates for MD with atypical symptoms was not significantly different in Milaneschi et al. (2016)<sup>17</sup>, 0.43 (95% CI=0.04-0.82) vs 0.38 (95% CI=0.05-0.71); in Milaneschi at al. (2017)<sup>18</sup>, 0.11 (95% CI=0.05-0.17) vs 0.11 (95% CI=0.07-0.15); and in Badini et al. (2020)<sup>16</sup>, 0.14 (95% CI=0.03-0.15) vs 0.12 (95% CI=0.08-0.16).

<sup>+++</sup> Compared with MD without trauma, *h*<sup>2</sup><sub>g</sub> estimate was higher for MD with trauma in Coleman et al. (2020)<sup>22</sup>, 0.24 (95% CI=0.18-0.31) vs 0.12 (95% CI=0.07-0.16), but lower in Peterson et al. (2018)<sup>23</sup>, 0.34 (95% CI=0.03-0.65) vs 0.38 (95% CI=0.29-0.47).

Measure	Description	Criteria	Derive method
		Life-time CIDI MD	
		5/8 criteria A1-A9 (lack A5) with at least one criteria A1 or A2 plus	
		criteria BCDE as below:	Life-time CIDI MD
		A1 (UKB 20446)	UKB20446 = 1 or UKB20441 = 1
		A2 (UKB 20441)	and
		A3 (UKB 20536)	sum UKB(20446, 20441, 20536, 20532, 20449, 20450,
		A4 (UKB 20532)	20435, 20437) >=5
		A6 (UKB 20449)	and
		A7 (UKB 20450)	UKB20440 = 3
		A8 (UKB 20435)	and
		A9 (UKB 20437)	UKB41202 != (F10-F19, F20-F29, F30)
		B - Impact on normal roles during worst period of depression (UKB	and
		20440)	UKB41204 != (F10-F19, F20-F29, F30)
	Lifetime or current MDD	C - Not substance abuse (UKB 41202 + 41204)	Current CIDI MD
CIDI-SF based MD		D- Not SCZ or psychotic (UKB 41202 + 41204	UKB20510 = 1 or UKB20514 = 1
	according to DSM-V criteria	E - Not Maniac (UKB 41202 + 41204)	and
		Current CIDI MD	sum UKB(20510, 20514, 20511, 20517, 20518, 20519
		<ul> <li>- 5/9 criteria with at least one criteria A1 or A2 (each satisfied A</li> </ul>	20507, 20508, 20513) >=5
		criteria scores 1)	and
		A1 (UKB 20510) = 4	UKB20440 = 3
		A2 (UKB 20514) = 4	and
		A3 (UKB 20511) = 4	UKB41202 != (F10-F19, F20-F29, F30)
		A4 (UKB 20517) = 4	and
		A5 (UKB 20518) = 4	UKB41204 != (F10-F19, F20-F29, F30)
		A6 (UKB 20519) = 4	CIDI-based MD
		A7 (UKB 20507) = 4	Life-time CIDI MD = 1
		A8 (UKB 20508) = 4	or Current CIDI MDD = 1
		A9 (UKB 20513) = 4	
		B - Plus Impact on normal roles during worst period of depression	

#### Table S2 Method to derive of MD cases, control and exclusion criteria in UKB

		(UKB 20440) C - Plus Not substance abuse (UKB 41202 + 41204) D - Plus Not SCZ or psychotic (UKB 41202 + 41204) E - Plus Not Maniac (UKB 41202 + 41204)	
ICD-coded MD	Clinician diagnosis of MDD	Any primary or secondary diagnosis of a depressive mood disorder from linked hospital admission records (UKB 41202 + 41204)	UKB41202 = F32/F33/F34/F38/F39 or UKB41204 = F32/F33/F34/F38/F39
Probable MD		Depressed/down for a whole week (UKB: 4598); And At least 2 weeks duration (UKB: 4609); And Ever seen a GP or psychiatrist for nerves, anxiety or depression" (UKB 2090 + 2010) Or Ever anhedonia for a whole week (UKB 4631); plus At least 2 weeks duration (UKB 5375); And Ever seen a GP or psychiatrist for nerves, anxiety, or depression (UKB 2090 + 2010)	UKB20126 = 3/4/5
Self-reported MD	Self-reported ever had MDD diagnosis or non-cancer diseases including MD	Self-reported depression (UKB 20002) or Self-reported Mental health problems ever diagnosed by a professional (UKB 20544)	UKB20002 = 1286 or UKB20544 = 11
MD cardinal symptoms	Ever had indication of depression	Ever had prolonged loss of interest in normal activities (UKB 20441); or prolonged feelings of sadness or depression (UKB 20446)	UKB20441 = 1 or UKB20446 = 1

MD broad phenotype	The MD broad definition to define cases in the study	Meet at least 1 measure 1-5	CIDI-SF based MD = 1 or ICD-coded MD = 1 or Probable MD = 1 or Self-reported MD = 1 or MD cardinal symptoms = 1
Help-seeking MD	Self-reported help-seeking behavior for mental health difficulties	Ever seen a general practitioner (GP) for nerves, anxiety, tension or depression (UKB 2090) or Ever seen a psychiatrist for nerves, anxiety, tension or depression (UKB 2010)	UKB2090 = 1 or UKB2100 = 1
Antidepressant use	Self-reported use of antidepressants as regular medication and health supplements	Reported use of any antidepressant (UKB 20003)	UKB20003 = any code in the list of antidepressants
Control MD	Controls of MD population	Not meeting any of 7 MD definitions 1-7 as above	CIDI-SF based MD != 1 and ICD-coded MD != 1 and Probable MD != 1 and Self-reported MD != 1 and MD cardinal symptoms != 1 and Help-seeking MD !=1 and Antidepressant use != 1
Control postpartum MD	Controls of PPD population	Women (UKB 31) and Have given >= 1 live birth (UKB 2734)	Control MD = 1 and UKB31 = 0

		and Not meeting any of 7 MD definitions 1-7 as above	and UKB2734 > 0
Control comorbid anxiety MD	Control for cases in the comorbid anxiety subtype	Not meeting any of 7 MD definitions 1-7 as above and Not having anxiety disorder F40/F41 (UKB 41202, 41204)	Control MD = 1 and UKB41202 != (F40, F41) and UKB41204 != (F40, F41)
Exclusion criteria	Criteria to excluded cases and controls	Do not have diagnosis of SCZ/psychosis (F20-F29), BP (F31) and Manias (F30) (UKB 41202 + 41204) and Do not used antipsychotics or lithium (UKB 20003)	UKB41202 != (F10-F19, F20-F29, F30) and UKB41204 != (F10-F19, F20-F29, F30) and UKB20003 != any code in the list of antipsychotics and lithium

\*Note: != means NOT EQUAL; coding 0 = No; 1 = Yes for binary variables; otherwise, check https://biobank.ctsu.ox.ac.uk/crystal/index.cgi

Source	MD definitions	N (%*)	Derived subtype
MHQ online questionnaire	CIDI-SF based MD	17,121 (3.76%)	- Recurrence
Hospital admission records	ICD-coded MD	12,135 (2.66%)	<ul> <li>Severity</li> <li>Comorbid anxiety</li> <li>Postpartum</li> </ul>
Touchscreen questionnaire (mental health)	Probable MD	28,628 (6.28%)	- Recurrence - Severity
Nurse interview	Self-reported MD	50,857 (11.15%)	<ul><li>Comorbid anxiety</li><li>Postpartum</li></ul>
MHQ online questionnaire	MD cardinal symptoms	83,774 (18.37%)	<ul> <li>Age at onset</li> <li>Suicidal thought</li> <li>Atypical-like features</li> <li>Impairment</li> </ul>

Table S3 MD definitions and derived subtypes

CIDI-SF = Composite International Diagnostic Interview Short Form | MHQ = Mental health questionnaire \*Proportion of total 459,590 included sample

### Table S4 Method to derive MD subtypes in UKB data

Subtypes	Description	Subtype within MD broad phenotype <sup>a</sup>	Subtype within CIDI-SF based MD <sup>b</sup>			
Vegetative sympto	Vegetative symptoms					
Atypical-like features	MD with atypical features Hypersomnia (UKB20534) and weight gain (UKB20536)	MD broad phenotype = 1 and (UKB20534 = 1 and UKB20536 = 1)	CIDI-SF-based MD = 1 and (UKB20534 = 1 and UKB20536 = 1)			
Non-atypical-like features	MD without atypical features. i.e., did not have hypersomnia and weight gain at the same time	MD broad phenotype = 1 and (UKB20534 = 0 and/or UKB20536 = 0)	CIDI-SF-based MD = 1 and (UKB20534 = 0 and/or UKB20536 = 0)			
Severity						
Severe	Severe episode MD ascertained by self-report and ICD diagnostic codes (UKB20126, UKB41202, UKB41204)	MD broad phenotype = 1 and (UKB20126 = 3 or UKB41202 = F322/F323/ F332/F333 or UKB41204 = F322/F323/ F332/F333)	CIDI-SF-based MD = 1 and (UKB20126 = 3 or UKB41202 = F322/F323/ F332/F333 or UKB41204 = F322/F323/ F332/F333)			
Mild/moderate	Mild and moderate MD ascertained by self-report and ICD diagnostic codes (UKB20126, UKB41202, UKB41204)	MD broad phenotype = 1 and (UKB20126 = 4 or UKB41202 = F320/F321/ F330/F331 or UKB41204 = F320/F321/F330/F331) and not included in severe subtype	CIDI-SF-based MD = 1 and (UKB20126 = 4 or UKB41202 = F320/F321/ F330/F331 or UKB41204 = F320/F321/F330/F331) and not included in severe CIDI-SF -based subtype			
Comorbid anxiety						
Comorbid anxiety	MD WITH comorbid anxiety, panic attacks, social anxiety/phobia (UKB 20544, UKB41202, UKB41204)	MD broad phenotype = 1 and (UKB20544 = 1/6/15 or UKB41202 = F40, F41 or UKB41204 = F40, F41)	CIDI-SF-based MD = 1 and (UKB20544 = 1/6/15 or UKB41202 = F40, F41 or UKB41204 = F40, F41)			
Non-comorbid anxiety	MD WITHOUT comorbid anxiety, panic attacks, social anxiety/phobia (UKB 20544, UKB41202, UKB41204)	MD broad phenotype = 1 and (UKB20544 != 1/6/15 and UKB41202 != F40, F41 and UKB41204 != F40, F41)	CIDI-SF-based MDD = 1 and (UKB20544 != 1/6/15 and UKB41202 != F40, F41 and UKB41204 != F40, F41)			
Age at onset						

Early onset	Age at first episode of depression ≤ 30 (UKB20433)	MD broad phenotype = 1 and UKB20433 = [2,30]	CIDI-SF-based MD = 1 and UKB20433 = [2,30]
Late onset	Age at first episode of depression $\geq$ 44 (UKB20433)	MD broad phenotype = 1 and UKB20433 = (43,78]	CIDI-SF-based MD = 1 and UKB20433 = (43,78]
Recurrence			
Recurrent	MD with recurrent episodes (UKB20126, UKB41202, UKB41204)	MD broad phenotype = 1 and (UKB20126 = $3/4$ or (CIDI-SF-based MDD = 1 and UKB20442 $\geq$ 2) or UKB41202 = F33 or UKB41204 = F33)	CIDI-SF-based MD = 1 and (UKB20126 = 3/4 or (CIDI-SF-based MDD = 1 and UKB20442 ≥ 2) or UKB41202 = F33 or UKB41204 = F33)
Single	MD with single episode (UKB20126, UKB41202, UKB41204)	MD broad phenotype = 1 and (UKB20126 = 5 or (CIDI-SF-based MDD = 1 and UKB20442 < 2) or UKB41202 = F32 or UKB41204 = F32) and Not in recurrent subtype	CIDI-SF-based MD = 1 and (UKB20126 = 5 or (CIDI-SF-based MDD = 1 and UKB20442 < 2) or UKB41202 = F32 or UKB41204 = F32) and Not in CIDI-SF-based recurrent MD subtype
Suicidality			
Yes	Having suicidal thought during the worst period of or recent thoughts of suicide or self-harm more than half of days or nearly every day (UKB20437, UKB20513)	MD broad phenotype = 1 and (UKB20437 = 1 or 20513 = 3/4)	CIDI-SF-based MD = 1 and (UKB20437 = 1 or 20513 = 3/4)
No	Not having suicidal thought or recent thoughts of suicide or self-harm (UKB20437, UKB20513)	MD broad phenotype = 1 and (UKB20437 = 0 and UKB20513 = 1)	CIDI-SF-based MD = 1 and (UKB20437 = 0 and UKB20513 = 1)
Impairment			
Mild	Impact on normal roles during worst period of depression is not at all or a little (UKB20440)	MD broad phenotype = 1 and UKB20440 = 0/1	N/A
Moderate	Impact on normal roles during worst period of depression somewhat (UKB20440)	MD broad phenotype = 1 and UKB20440 = 2	N/A

Severe	Impact on normal roles during worst period of depression a lot (UKB20440)	MD broad phenotype = 1 and UKB20440 = 3	N/A
Postpartum MD			
MD relating to child birth	MD relating to child birth ascertained by self-report (UKB 20002, UKB 20445) and ICD code (UKB: 41202 and 41204)	MD broad phenotype = 1 and (UKB20002 = 1531 or UKB20445 = 1 or UKB41202 = F53 or UKB41204 = F53)	CIDI-SF-based MD = 1 and (UKB20002 = 1531 or UKB20445 = 1 or UKB41202 = F53 or UKB41204 = F53)

<sup>a</sup>Subtypes in primary analyse | <sup>b</sup>Subtypes in sensitivity analyses

!= means NOT EQUAL | coding 0 = No; 1 = Yes for binary variables; otherwise, check https://biobank.ctsu.ox.ac.uk/crystal/index.cgi

### Table S5 Medication list

$ID^{\dagger}$	Medication name	ID <sup>†</sup>	Medication name
Antidepressant			
1140879616	amitriptyline	1141151978	reboxetine
1140921600	citalopram	1141152736	zispin
1140879540	fluoxetine	1140867640	doxepin
1140867878	sertraline	1140867920	moclobemide
1140916282	venlafaxine	1140867850	phenelzine
1140909806	dosulepin	1140879544	fluvoxamine
1140867888	paroxetine	1141200570	yentreve
1141152732	mirtazapine	1140867934	triptafen
1141180212	escitalopram	1140867758	surmontil
1140879634	trazodone	1140867914	tranylcypromine
1140867876	prozac	1140867820	allegron
1140882236	seroxat	1141151982	edronax
1141190158	cipralex	1140882244	molipaxin
1141200564	duloxetine	1140879556	mianserin
1140867726	lofepramine	1140867852	nardil
1140879620	clomipramine	1140867860	faverin
1140867818	nortriptyline	1140917460	nefazodone
1140879630	imipramine	1140867938	Amitriptyline + chlordiazepoxide
1140879628	dothiepin	1140867856	isocarboxazid
1141151946	cipramil	1140867922	manerix
1140867948	amitriptyline	1140910820	maoi
1140867624	prothiaden	1140882312	sinequan
1140867756	trimipramine	1140867944	Tranylcypromine + trifluoperazine
1140867884	lustral	1140867784	ludiomil
1141201834	cymbalta	1140867812	norval
1140867690	anafranil	1140867668	tryptizol
Antipsychotic			
1140928916	olanzapine	1141202024	abilify
1141152848	quetiapine	1140882098	fluphenazine
1140867444	risperidone	1140867184	haldol
1140879658	chlorpromazine	1140867092	serenace
1140868120	trifluoperazine	1140882320	clozaril
1141153490	amisulpride	1140910358	срг
1140867304	sulpiride	1140867208	perphenazine
1141152860	seroquel	1140909802	levomepromazine
1140867168	haloperidol	1140867134	pericyazine
1141195974	aripiprazole	1140867306	dolmatil
1140867244	stelazine	1140867210	fentazin

1140867152	depixol	1140867398	fluphenazine
1140909800	flupentixol	1140867078	benperidol
1140867420	clozapine	1140867218	pimozide
1140879746	promazine	1141201792	zaponex
1141177762	risperdal	1141200458	denzapine
1140867456	modecate	1140867136	neulactil
1140867952	fluanxol	1140879750	thioridazine
1140867150	flupenthixol	1140867180	dozic
1141167976	zyprexa	1140867546	fluspirilene
1140882100	zuclopenthixol	1140928260	panadeine
1140867342	clopixol	1140927956	sertindole
1140863416	largactil		
Lithium			
1140867490	lithium product	1140867504	priadel 200mg m/r tablet
1140867494	camcolit 250 tablet	1140867518	litarex 564mg m/r tablet
1140867498	liskonum 450mg m/r tablet	1140867520	li-liquid 5.4mmol/5ml oral solution
1140867500	phasal 300mg m/r tablet		

This list is from Davis et al., 2019 (PMC6877131)<sup>26</sup> | <sup>+</sup>ID in UKB data (field 20003)

Phenotype	h <sup>2</sup> <sub>SNP</sub> observed scale	SE observed scale	N case	N control	N effective <sup>a</sup>	Sample case prevalence <sup>b</sup>	Population case prevalence <sup>c</sup>	Population control prevalence <sup>d</sup>	Subtype proportion in literature	Source for subtype proportion	h² <sub>s№</sub> liability Yap <sup>e</sup>	SE liability Yap <sup>e</sup>	h² <sub>s№</sub> liability Lee <sup>f</sup>	SE liability Lee <sup>f</sup>	h <sup>2</sup> <sub>SNP</sub> observed 50/50 <sup>g</sup>	SE observed 50/50 <sup>g</sup>
Atypical-like																
features	0.0086	0.0019	2904	250229	11483	0.0115	0.0450	0.85	0.30	PMID:	0.1335	0.0295	0.1555	0.0344	0.1904	0.0416
Non-atypical-										29033570						
like features	0.0400	0.0024	46900	250229	157988	0.1578	0.1050	0.85	0.70		0.0748	0.0045	0.0804	0.0048	0.0753	0.0046
Severe	0.0143	0.0022	7923	250229	30719	0.0307	0.0750	0.85	0.50	PMID:	0.1028	0.0158	0.1154	0.0178	0.1202	0.0184
Mild/ Moderate	0.0159	0.0018	11300	250229	43247	0.0432	0.0750	0.85	0.50	29450462	0.0823	0.0093	0.0924	0.0105	0.0963	0.0110
Co. Anxiety	0.0416	0.0023	24543	249062	89366	0.0897	0.0825	0.85	0.55		0.1135	0.0063	0.1261	0.0070	0.1273	0.0072
Non-co.	0.0410	0.0025	24343	243002	05500	0.0057	0.0025	0.05	0.55	PMID:	0.1155	0.0005	0.1201	0.0070	0.1275	0.0072
anxiety	0.0268	0.0022	16480	249062	61829	0.0621	0.0675	0.85	0.45	11098417	0.0943	0.0077	0.1070	0.0088	0.1152	0.0096
•										3 first						
Early onset	0.0489	0.0027	29292	250229	104890	0.1048	0.0563	0.85	0.375	octiles	0.0997	0.0055	0.1146	0.0063	0.1304	0.0071
										3 last						
Late onset	0.0153	0.0019	27796	250229	100068	0.1000	0.0563	0.85	0.375	octiles	0.0325	0.0040	0.0374	0.0046	0.0426	0.0053
Recurrent	0.0410	0.0025	30219	250229	107851	0.1078	0.0525	0.85	0.35	PMID:	0.0794	0.0048	0.0918	0.0056	0.1067	0.0066
Single	0.0222	0.0021	20973	250229	77404	0.0773	0.0975	0.85	0.65	20003092	0.0747	0.0071	0.0812	0.0077	0.0822	0.0083
Suicidal	0.0425	0.0025	40976	250229	140841	0.1407	0.0900	0.85	0.60	PMID:	0.0814	0.0048	0.0894	0.0053	0.0879	0.0053
Non-suicidal	0.0359	0.0023	37140	250229	129360	0.1292	0.0600	0.85	0.40	14628986	0.0625	0.0040	0.0715	0.0046	0.0798	0.0051
Mild impair	0.0222	0.0019	28721	250229	103055	0.1030	0.0300	0.85	0.20		0.0372	0.0032	0.0439	0.0038	0.0600	0.0052
Moderate										PMID:						
impair	0.0338	0.0025	28991	250229	103924	0.1038	0.0300	0.85	0.20	15930066	0.0562	0.0042	0.0665	0.0049	0.0908	0.0066
Severe impair	0.0382	0.0025	25825	250229	93636	0.0936	0.0900	0.85	0.60		0.1042	0.0068	0.1145	0.0075	0.1127	0.0073
										PMID:						
Postpartum	0.0250	0.0053	6333	95736	23760	0.0620	0.10	0.90	0.10	16260528	0.1131	0.0240	0.1131	0.0240	0.1073	0.0227
CIDI-based																
MD	0.0315	0.0024	17121	250229		0.0640	0.15	0.85			0.1572	0.0120	0.1572	0.0120	0.1312	0.0102
ICD-coded MD	0.0350	0.0025	12135	250229		0.0463	0.15	0.85			0.2370	0.0169	0.2370	0.0169	0.1983	0.0142
Probable MD	0.0299	0.0023	28628	250229		0.1027	0.15	0.85			0.0970	0.0075	0.0970	0.0075	0.0811	0.0063
Self-reported																
MD	0.0628	0.0096	50857	250229		0.1689	0.15	0.85			0.1338	0.0205	0.1338	0.0205	0.1069	0.0048
Cardinal MD	0.0579	0.0025	83774	250229		0.2508	0.15	0.85			0.0921	0.0040	0.0921	0.0040	0.077	0.0034
Broad MD	0.0547	0.0024	124121	250229		0.3316	0.15	0.85			0.0738	0.0032	0.0738	0.0032	0.0618	0.0027

# Table S6 Prevalence of subtypes to convert $h_g^2$ from observed to liability scale

<sup>a</sup>N\_effective =4\*p\*(1-p)\*N, with p = sample case proportion, N = total sample size

<sup>b</sup>Sample case prevalence = Ncase/(Ncase + Ncontrol)

<sup>c</sup>Population case prevalence = 0.15\*case proportion (except PPD)

<sup>d</sup>Population control prevalence = 85% (except PPD). For MD phenotypes, population case prevalence = estimated lifetime prevalence of MD 15%, and population control prevalence = 85%

<sup>e</sup>Heritability and SE were converted from observed scale to liability scale using the method from Yap et al. (2018)<sup>11</sup>

<sup>f</sup>Heritability and SE were converted from observed scale to liability scale using the equation 17 in Lee at al. (2011)<sup>10</sup>, same as used in LDSC software

<sup>g</sup>Heritability and SE on observed scale using based on 50:50 case-control ascertainment

	Table 37 Signi		in busey		ouu m	pinein	stype et	1710			Significant		
CHR	Region	rsID	POS	A1/A2	AF1	OR	SE	Р	Nearest Gene	Mapped Gene(s)	in previous large GWAS <sup>+</sup>	Significant in broad MD GWAS	P-values in GWAS of other subtype in comparison
Non-a	atypical-like features												MD with atypical-like features
1	72511514-72838406	rs66495454	72748567	G/GTCCT	0.62	0.9501	0.0073	1.82e-12	NEGR1	NEGR1	PGC+ UKB, Top10K	Yes	2.51e-03
6	27309779-29548089	rs9393925	28682442	T/C	0.14	0.9424	0.0101	3.71e-09	RPSAP2	>10 genes	PGC+ UKB, Top10K	Yes	1.18e-01
12	113349833-113349833	rs55676265	113349833	A/G	0.79	0.9535	0.0086	3.40e-08	OAS1:RP1- 71H24.1	OAS1		No	7.98e-01
13	53608084-53842904	rs2806950	53646197	G/A	0.38	1.0446	0.0073	1.80e-09	OLFM4	OLFM4	Тор10К	Yes	6.54e-03
17	56424710-56451552	rs56058331	56427128	G/A	0.58	0.9615	0.0071	3.12e-08	BZRAP1- AS1:SUPT4H1	SUPT4H1, RNF43	*	No	8.17e-01
19	4944555-5022857	rs59562763	4969102	G/GC	0.65	0.9588	0.0074	1.04e-08	KDM4B	KDM4B	*	Yes	5.77e-02
Anxie	ty												Non-anxiety
1	72544704-72748567	rs66495454	72748567	G/GTCCT	0.62	0.9465	0.0097	1.51e-08	NEGR1	NEGR1	PGC+ UKB, Top10K	Yes	5.36e-04
7	12233848-12286050	rs3807866	12250378	G/A	0.59	0.9432	0.0095	7.67e-10	TMEM106B	TMEM106B	PGC+ UKB, Top10K	Yes	4.03e-03
9	11275587-11771159	rs958538	11522951	T/C	0.75	1.0663	0.0109	3.72e-09	RP11-23D5.1		PGC+ UKB, Top10K	No	8.49e-01
14	103833065-104000802	14:10396454 5_TA_T	103964545	TA/T	0.30	0.9443	0.0104	3.75e-08	MARK3	MARK3, CKB, TRMT61A	PGC+ UKB, Top10K	Yes	1.73e-03
Early	onset												Late onset
1	72511514-72838406	rs7542974	72544704	G/A	0.75	0.9282	0.0100	7.79e-14	NEGR1	NEGR1	PGC+ UKB, Top10K	Yes	6.72e-02
2	34996836- 35088235	2:35034680_ CGA_C	35034680	CGA/C	0.50	1.0496	0.0087	2.84e-08	AC012593.1		*	No	4.94e-02
3	85517112-86192846	rs10865612	85868529	T/C	0.65	0.9380	0.0090	1.11e-12	CADM2:CADM 2-AS2	CADM2	*	No	9.21e-01
6	27374680-27486633	rs6914846	27410679	A/G	0.40	0.9522	0.0090	4.50e-08	ZNF184	ZNF391, ZNF184	PGC+ UKB, Top10K	Yes	8.07e-05
6	29530868-29530868	rs362529	29530868	C/T	0.85	0.9347	0.0120	1.84e-08	GABBR1	UBD, GABBR1	*	No	2.41e-01
7	24548616-24801999	rs2711093	24617290	C/T	0.70	0.9472	0.0095	1.00e-08	MPP6	MPP6, DFNA5		Yes	2.67e-02
9	16713666-16784682	rs35261422	16754554	A/AT	0.78	1.0607	0.0104	1.69e-08	BNC2	BNC2	*	No	9.07e-01

### Table S7 Significant loci in MD subtypes and broad MD phenotype GWAS

10	126711107-126738471	rs34260682	126711499	G/A	0.91	1.0892	0.0156	4.51e-08	CTBP2	CTBP2		No	6.83e-02
13	53608084-53675539	rs3803259	53613331	G/C	0.48	1.0506	0.0087	1.72e-08	OLFM4	OLFM4	Тор10К	Yes	2.25e-04
14	60179792-60663420	rs216519	60653477	C/A	0.62	0.9518	0.0088	2.31e-08	PSMA3P	RTN1, LRRC9, PCNXL4, DHRS7		No	1.69e-01
16	13665985-13805809	rs56225373	13755408	T/G	0.86	0.9264	0.0126	1.31e-09	U95743.1		PGC+ UKB, Top10K	No	4.79e-01
19	18182266-18279816	rs11667720	18193751	G/C	0.57	0.9471	0.0090	1.52e-09	IL12RB1	IL12RB1, MAST3, PIK3R2, IFI30	*	No	6.28e-02
20	59827231-59827231	rs143502921	59827231	G/C	0.82	0.9196	0.0126	2.48e-11	CDH4	CDH4	*	Yes	8.19e-02
Recu	rrent												Single
2	15311954-15468791	rs6431690	15443525	T/C	0.55	1.0530	0.0086	1.76e-09	NBAS	NBAS		No	3.22e-04
2	152886708-153120132	rs62175074	152886708	T/C	0.79	0.9415	0.0109	3.31e-08	CACNB4	CACNB4	*	No	2.41e-02
2	212702426-212778384	rs74338595	212749786	T/C	0.71	1.0534	0.0094	2.87e-08	ERBB4	ERBB4		No	8.71e-01
5	164467717-164588817	rs543533963	164474868	C/T	0.45	0.9533	0.0087	3.98e-08	CTC-340A15.2		PGC+ UKB, Top10K	No	2.81e-01
6	26309908-29607101	rs1233393	29549653	C/G	0.87	1.0869	0.0127	5.98e-11	GABBR1	>10 genes	PGC+ UKB, Top10K	Yes	2.45e-03
11	88472034-88978545	rs1942496	88840925	G/A	0.51	1.0513	0.0086	5.81e-09	AP001482.1	GRM5, TYR	PGC+ UKB, Top10K	Yes	3.86e-03
19	31891006-31927547	rs2111530	31891006	A/G	0.61	0.9513	0.0088	1.20e-08	AC007796.1			Yes	4.59e-01
Suicio	dal												Non-suicide
1	109873290-110040460	rs11590351	110035159	T/C	0.75	0.9516	0.0086	8.54e-09	ATXN7L2	SORT1, PSMA5, SYPL2, ATXN7L2, CYB561D1, AMIGO1		No	4.77e-03
4	2412967-2439670	rs113065538	2420428	C/A	0.35	1.0441	0.0078	3.41e-08	ZFYVE28	ZFYVE28		No	2.33e-02
11	90528418-90646073	rs10830592	90592959	A/G	0.32	0.9565	0.0080	2.43e-08	DISC1FP1			No	6.31e-02
Non-	suicidal												Suicide
1	72544704-72838406	rs66495454	72748567	G/GTCCT	0.62	0.9510	0.0081	5.79e-10	NEGR1	NEGR1	PGC+ UKB, Top10K	Yes	8.62e-08
1	239697408-239760514	rs12118109	239760514	G/A	0.96	0.8982	0.0197	4.68e-08	CHRM3	CHRM3		No	8.03e-01
6	27374680-27486633	rs6914846	27410679	A/G	0.40	0.9559	0.0081	2.96e-08	ZNF184	ZNF391, ZNF184	PGC+ UKB, Top10K	Yes	2.18e-05

10	76463067-76506933	rs9733673	76504584	G/T	0.85	0.9358	0.0113	4.68e-09	RP11-383B24.3	ADK		No	9.58e-01	
15	83170194-83337059	rs35385880	83214764	с/ст	0.35	0.9545	0.0082	1.27e-08	RP11- 152F13.10:RP1 1- 379H8.1:CPEB	RPS17L, RP11- 152F13.10, RP11- 379H8.1, CPEB1, AP3B2	*	No	1.34e-03	
Mode	erate impairment												Mild	Severe
1	72748567-72838406	rs66495454	72748567	G/GTCCT	0.62	0.9428	0.0090	6.95e-11	NEGR1	NEGR1	PGC+ UKB, Top10K	Yes	4.23e-03	6.81e-09
1	243197475-243500994	rs4658548	243394093	C/T	0.63	1.0520	0.0090	1.82e-08	CEP170:AC092 782.1	CEP170, AC092782.1, SDCCAG8		No	1.25e-02	5.54e-02
16	10472145-10596428	rs141035531	10589515	C/G	0.98	0.8377	0.0311	1.28e-08	RNU6-633P	ATF7IP2	*	No	2.25e-03	2.45e-01
Seve	re impairment												Mild	Moderate
1	72511514-72748567	rs7542974	72544704	G/A	0.75	0.9402	0.0106	6.37e-09	NEGR1	NEGR1	PGC+ UKB, Top10K	Yes	1.21e-03	2.18e-06
5	164334125-164678946	rs10476484	164438264	A/G	0.73	0.9399	0.0103	2.13e-09	CTC-340A15.2		PGC+ UKB, Top10K	No	4.73e-01	1.73e-01
6	27321848-27476592	rs6456788	27422066	C/T	0.35	0.9485	0.0096	3.32e-08	ZNF184	ZNF391, ZNF184	PGC+ UKB, Top10K	Yes	1.82e-03	3.48e-04
6	27868792-29548089	rs9393925	28682442	T/C	0.14	0.9290	0.0131	2.01e-08	RPSAP2	>10 genes	PGC+ UKB, Top10K	Yes	4.04e-03	1.53e-02
13	53608084-53675691	rs12552	53625781	A/G	0.44	1.0603	0.0093	2.55e-10	OLFM4		Тор10К	Yes	1.21e-01	2.16e-07
PPD														
2	189234143-189682431	rs11683671	189669039	C/A	0.93	0.8152	0.0367	2.68e-08	AC079613.1	GULP1		No	-	
MDb	proad phenotype													
1	37663818-37680479	rs215849	37677592	C/G	0.76	0.9669	0.0058	5.95e-09	RNU6-636P		*	-	-	
1	71815804-73699761	rs66495454	72748567	G/GTCCT	0.62	0.9593	0.0050	9.32e-17	NEGR1	NEGR1	PGC+ UKB, Top10K	-	-	
1	197342380-197813558	rs12123169	197780966	T/A	0.79	1.0360	0.0059	2.51e-09	DENND1B	CRB1, DENND1B	PGC+ UKB, Top10K	-	-	
2	23178683-23183651	rs6744716	23181209	T/A	0.69	0.9716	0.0052	3.02e-08	AC016768.1			-	-	
2	34996836-35092802	rs2083210	35027554	G/T	0.56	1.0275	0.0049	2.62e-08	AC012593.1			-	-	
2	155654466-156116188	rs1037094	155656548	C/A	0.79	1.0338	0.0060	2.50e-08	КСЛЈЗ	KCNJ3		-	-	
5	87981030-88175251	rs28712135	88084016	T/A	0.53	1.0288	0.0049	6.33e-09	MEF2C	MEF2C	Top10K*	-	-	

	1	1				1	1						
5	103671867-104082179	rs30266	103972357	G/A	0.67	0.9699	0.0051	2.92e-09	RP11-6N13.1		PGC+ UKB, Top10K	-	-
6	25417423-29607101	rs10807023	27410220	G/A	0.38	0.9644	0.0050	2.79e-13	ZNF184	>10 genes	PGC+UKB, Top10K	-	-
7	12233848-12286050	rs3807865	12250402	G/A	0.59	0.9731	0.0049	2.46e-08	TMEM106B	TMEM106B	PGC+UKB, Top10K	-	-
7	24590979-24779987	rs2529047	24598708	G/A	0.70	0.9696	0.0053	6.20e-09	MPP6	MPP6, DFNA5		-	-
11	31808280-31856654	rs7942007	31835418	A/G	0.81	0.9663	0.0062	3.43e-08	PAX6:RCN1	ELP4, PAX6, RCN1	Тор10К	-	-
11	88470041-89026407	11:88769807	88769807	GGCAAG ACTAT TAATCAG TATTT GTACTCA AATTT GCCCCAA AGTC CCTCAAC TA/G	0.42	1.0317	0.0049	2.52e-10	GRM5	GRM5, TYR	PGC+ UKB, Top10K	-	-
13	53608084-53675539	rs3803259	53613331	G/C	0.48	1.0327	0.0049	5.84e-11	OLFM4	OLFM4	PGC+ UKB, Top10K	-	-
13	69779070-70024608	rs7989827	69857608	T/G	0.52	1.0273	0.0048	2.47e-08	LINC00383			-	-
14	60155307-60247284	14:60156702 _CT_C	60156702	CT/C	0.35	1.0294	0.0052	2.27e-08	RTN1	RTN1	*	-	-
14	103833065-104093521	rs2071408	103987078	G/A	0.63	1.0333	0.0050	7.46e-11	СКВ	MARK3, CKB, TRMT61A, BAG5, KLC1, RP11- 73M18.2, APOPT1	PGC+ UKB, Top10K	-	-
15	74010301-74062710	rs4327001	74010301	G/A	0.59	0.9732	0.0049	3.24e-08	CD276	CD276, C15orf59		-	-
18	50364022-51059160	rs112633410	50740013	G/A	0.57	0.9713	0.0049	2.51e-09	DCC	DCC	PGC+ UKB, Top10K	-	-
19	4944555-5022857	rs58324296	4969199	A/C	0.65	0.9715	0.0051	1.18e-08	KDM4B	KDM4B		-	-
19	31891006-31927547	rs2111530	31891006	A/G	0.60	0.9732	0.0050	4.25e-08	AC007796.1			-	-
20	59827231-59827231	rs143502921	59827231	G/C	0.82	0.9539	0.0070	2.08e-11	CDH4	CDH4	*	-	-

\*Some variants in those loci were not analyzed in PGC+UKB GWAS, which might be excluded in quality control or not examined.

<sup>†</sup>Top10K: Data contains genome-wide summary statistics of the most informative 10,000 variants from a meta-analysis of the 33 cohorts of the Psychiatric Genomics Consortium, the broad depression phenotype in the full release of the UK Biobank and 23andMe data

PGC+UKB: Data contains genome-wide summary statistics from a meta-analysis of the 33 cohorts of the Psychiatric Genomics Consortium (excluding UK Biobank and 23 and Me data) and the broad depression phenotype in the full release of the UK Biobank

Citation: Howard et al (2019) [dataset]<sup>27</sup>.

Col 1 (CHR): Chromosome of the locus

- Col 2 (Region): Start and end position of the locus
- Col 3 (rsID): RsID of the lead SNP
- Col 4 (POS): Position of lead SNP on hg19
- Col 5 (A1/A2): Effect/non-effect allele of the lead SNP
- Col 6 (AF1): Allele frequency of effect allele of the lead SNP in study sample
- Col 7 (OR): Odd ratio of the lead SNP which was converted from beta coefficients in the GWAS result after correcting for sample case-control ascertainment
- Col 8 (SE): Standard error of log(OR)
- Col 9 (P): P-value of the lead SNP
- Col 10 (Nearest Gene): The nearest Gene of the lead SNP based on ANNOVAR annotations
- Col 11 (Mapped gene): Positional mapped gene. Loci was mapped to genes up to 10 kb
- Col 12 (Significant in previous large GWAS): If the SNPs were significant in the previous 2 large GWAS, Top10K and PGC+UKB
- Col 13 (Significant in broad MD GWAS): Checked if the subtype-specific significant SNPs were also significant in the broad MD GWAS
- Col 14 (P-values in GWAS of other subtype in comparison): P-values of the SNPs in the GWAS of the other subtype in the same comparison group

	N case <sup>a</sup>	N control <sup>b</sup>	Sample case prevalence <sup>c</sup>	N effective	h <sup>2</sup> <sub>SNP</sub> observed scale <sup>d</sup>	SE observed scale <sup>d</sup>	h <sup>2</sup> <sub>SNP</sub> observed 50/50 <sup>e</sup>	SE observed 50/50 <sup>e</sup>	h <sup>2</sup> <sub>SNP</sub> liability Yap <sup>f</sup>	SE liability Yap <sup>f</sup>	r <sub>g</sub>	Se r <sub>g</sub>	95% CI r <sub>g</sub>
Atypical-like features CIDI	1325	250229	0.0053	5272	0.0066	0.0019	0.3172	0.0884	0.2209	0.0636	0.5912	0.0942	0.4066;
Non-atypical-like features CIDI	11928	250229	0.0455	45541	0.0215	0.0022	0.1236	0.0129	0.123	0.0126			0.7758
Severe CIDI	1175	250229	0.0047	4678	0.0010	0.0022	0.0537	0.1162	0.0457	0.1006	0.9781	0.2724	0.4442;
Mild/moderate CIDI	1424	250229	0.0057	5664	0.0020	0.0016	0.0885	0.0692	0.0755	0.0604			1.5120
Co. anxiety CIDI	7303	249062	0.0285	28380	0.0217	0.0023	0.1965	0.021	0.1746	0.0185	0.7739	0.0634	0.6496;
Non-co. Anxiety CIDI	5920	249062	0.0232	23130	0.0125	0.002	0.1383	0.0217	0.1131	0.0181			0.8982
Early CIDI	6570	250229	0.0256	25608	0.0210	0.0022	0.2104	0.0225	0.161	0.0169	0.6021	0.084	0.4375;
Late CICI	5498	250229	0.0215	21519	0.0066	0.0018	0.0788	0.0213	0.0600	0.0164			0.7667
Recurrent CIDI	11094	250229	0.0425	42492	0.0265	0.0023	0.1632	0.0139	0.1213	0.0105	0.8402	0.0947	0.6546;
Single CIDI	5602	250229	0.0219	21917	0.0091	0.0018	0.1057	0.021	0.102	0.0202			1.0258
Suicide CIDI	10492	250229	0.0402	40279	0.0226	0.0022	0.1464	0.014	0.1356	0.0132	0.7641	0.0802	0.6069;
Non-suicide CIDI	5500	250229	0.0215	21527	0.0118	0.002	0.1404	0.0234	0.1098	0.0186			0.9213
PPD CIDI	1588	95736	0.0163	6248	0.0131	0.0046	0.2046	0.0712	0.2149	0.0754			

Table S8 SNP-heritability and genetic correlation for subtypes within CIDI-SF MD cases

<sup>a</sup>N case = number of cases as defined in *Supplementary table S4* and was used in GWAS

<sup>b</sup>N control = number of controls as defined in *Supplementary table S2* and was used in GWAS

<sup>c</sup>Sample case prevalence = N case/(N case + N control)

 ${}^{d}h^{2}{}_{SNP}$  and standard error (SE) were estimated on observed scale

 $e^{h^{2}_{SNP}}$  and SE were estimated on observed scale based on 50:50 case-control ascertainment

<sup>f</sup>h<sup>2</sup><sub>SNP</sub> and SE were converted from observed (see <sup>d</sup>) to liability scale using the same population case and control as in Supplementary table S6 using the conversion method in Yap et al. (2018)<sup>11</sup>

		Primary analysis	5		h	ndependent control a	nalysis	
Subtype	h <sup>2</sup> <sub>SNP</sub> observed scale <sup>a</sup> (se)	h² <sub>sNP</sub> liability Yap <sup>♭</sup> (Cl)	<i>h<sup>2</sup><sub>SNP</sub></i> observed 50/50 <sup>c</sup> (CI)	h <sup>2</sup> <sub>SNP</sub> observed scale <sup>a</sup> (se)	h <sup>2</sup> <sub>SNP</sub> liability Yap <sup>b</sup> (CI)	P-value <sup>d</sup>	h <sup>2</sup> <sub>SNP</sub> observed 50/50 <sup>c</sup> (CI)	P-value <sup>d</sup>
Early onset	0.049 (0.003)	0.100 (0.089-0.110)	0.130 (0.116-0.144)	0.078 (0.005)	0.097 (0.086-0.108)	2 206 - 10	0.127 (0.113-0.142)	1.400e-19
Late onset	0.015 (0.002)	0.033 (0.025-0.040)	0.043 (0.032-0.053)	0.025 (0.004)	0.033 (0.024-0.042)	2.306e-19	0.043 (0.031-0.054)	1.4000-19
Suicidal	0.043 (0.003)	0.081 (0.072-0.091)	0.088 (0.078-0.098)	0.063 (0.004)	0.078 (0.068-0.088)	0.017	0.085 (0.074-0.095)	0.520
Non-suicidal	0.036 (0.002)	0.063 (0.055-0.070)	0.080 (0.070-0.090)	0.056 (0.004)	0.062 (0.054-0.071)	0.017	0.080 (0.069-0.090)	0.520
Severe impaired	0.038 (0.003)	0.104 (0.091-0.118)	0.113 (0.098-0.127)	0.081 (0.006)	0.103 (0.089-0.118)	Severe-moderate 0.002e-09	0.112 (0.097-0.128)	Severe-moderate 0.017
Moderate impaired	0.034 (0.003)	0.056 (0.048-0.064)	0.091 (0.078-0.104)	0.067 (0.005)	0.054 (0.046-0.062)	Severe-mild 7.633e-15	0.087 (0.074-0.101)	Severe-mild 1.245e-06
Mild impaired	0.022 (0.002)	0.037 (0.031-0.043)	0.060 (0.050-0.070)	0.048 (0.005)	0.039 (0.031-0.047)	Moderate-mild 0.009	0.063 (0.050-0.075)	Moderate-mild 0.008

### Table S9 Compare subtype $h^2$ between primary analysis and independent controls analysis

<sup>a</sup>SNP-h<sup>2</sup> on observed scale

<sup>b</sup>SNP-h<sup>2</sup> on liability scale, converted from observed scale using method in Yap et al. (2018)<sup>11</sup>

<sup>c</sup>SNP-h<sup>2</sup> on observed scale based on 50:50 case-control ascertainment

<sup>d</sup>P-value derived from the Delta method which tests significant difference between estimates on liability scale and observed-h<sup>2</sup> 50/50

### III. SUPPLEMENTARY FIGURES

#### Figure S1 Included sample of study



Figure S1 Included sample

The dataset from UKB contains 502 616 observations. We excluded those who 1) did not have both genotype and phenotype data. 2) withdraw consent, 3) Low-quality genotype data, and 4) European ancestry outliers. Individuals without European ancestry were excluded by removing those whose first two principal components exceeded three standard deviations from the means of 1000 Genome European samples<sup>28</sup>. We retained 459 590 observations. We defined MD cases and controls as in *Supplementary table S2*. We identified 126,506 individuals who met at least one of the five MD case criteria. We used seven exclusion criteria to define controls (N=250 460) including five case criteria, and two additional criteria of help seeking for MD (N=38 177) and using antidepressant (N=175 367). Individuals who met the criteria for help seeking MD and using antidepressants thus fell into the 'neither case nor control' group.

Figure S2 SNP- heritability for MD definitions in UKB



Figure S2 SNP-heritability for MD definitions in UKB

Orange markers show  $h^2_{SNP}$  estimates on observed scale based on 50:50 case-control ascertainment<sup>9</sup>. Blue markers show point  $h^2_{SNP}$  estimates on liability scale, converted from observed scale using formula in Yap et al. (2018)<sup>11</sup>. Error bars show 95% confidence intervals.





Figure S3: SNP-heritability on liability scale using different conversion methods

The point presents *SNP-h*<sup>2</sup>. Error bars show 95% CI. **Red:** *SNP-h*<sup>2</sup> on observed scale based on 50:50 case-control ascertainment.

**Blue:** *SNP-h*<sup>2</sup> transformed from observed to liability scale using the standard conversion from Lee et al.  $(2011)^{10}$ . **Orange:** *SNP-h*<sup>2</sup> transformed from observed to liability scale based on the conversion from Yap et al.  $(2018)^{11}$  which takes into account extreme phenotype selection.

#### Figure S4 Subtype SNP-heritability estimated among all samples and unrelated samples



a. SNP-heritability observed scale 50/50

**Figure S4**: Subtype SNP-heritability estimated among all sample (GWAS using fastGWA) and unrelated sample (GWAS using PLINK). a. Estimates on observed scale based on 50:50 case-control ascertainment. b. Estimates on liability scale, converted from observed to liability using method from Yap et. al (2018)<sup>11</sup>. Error bars show 95% CI of the estimates.



### Figure S5 Phenotypic and genetic correlation across MD subtypes

**Figure S5**: Phenotypic and genetic correlation across MD subtypes. **Upper triangle**: pair-wise genetic correlations. **Lower triangle**: Phenotypic correlation for subtype cases only (because of common control group). "-1" indicates that subtype definitions were mutually exclusive (for subtype within same comparison group).

#### REFERENCES

- 1. Brailean A, Curtis J, Davis K, Dregan A, Hotopf M. Characteristics, comorbidities, and correlates of atypical depression: evidence from the UK Biobank Mental Health Survey. *Psychological Medicine* 2020; **50**(7): 1129-1138.
- Jiang L, Zheng Z, Qi T, Kemper KE, Wray NR, Visscher PM *et al.* A resource-efficient tool for mixed model association analysis of large-scale data. *Nature Genetics* 2019; 51(12): 1749-1755.
- 3. Smith DJ, Nicholl BI, Cullen B, Martin D, Ul-Haq Z, Evans J *et al.* Prevalence and Characteristics of Probable Major Depression and Bipolar Disorder within UK Biobank: Cross-Sectional Study of 172,751 Participants. *PLOS ONE* 2013; **8**(11): e75362.
- 4. Power RA, Tansey KE, Buttenschøn HN, Cohen-Woods S, Bigdeli T, Hall LS *et al.* Genome-wide Association for Major Depression Through Age at Onset Stratification: Major Depressive Disorder Working Group of the Psychiatric Genomics Consortium. *Biological Psychiatry* 2017; **81**(4): 325-335.
- 5. Hagenaars SP, Coleman JRI, Choi SW, Gaspar H, Adams MJ, Howard DM *et al.* Genetic comorbidity between major depression and cardio-metabolic traits, stratified by age at onset of major depression. *American Journal of Medical Genetics Part B: Neuropsychiatric Genetics* 2020; **183**(6): 309-330.
- 6. Cai N, Revez JA, Adams MJ, Andlauer TFM, Breen G, Byrne EM *et al.* Minimal phenotyping yields genome-wide association signals of low specificity for major depression. *Nature Genetics* 2020; **52**(4): 437-447.
- 7. Watanabe K, Taskesen E, van Bochoven A, Posthuma D. Functional mapping and annotation of genetic associations with FUMA. *Nature Communications* 2017; **8**(1): 1826.
- 8. Bulik-Sullivan BK, Loh P-R, Finucane HK, Ripke S, Yang J, Patterson N *et al.* LD Score regression distinguishes confounding from polygenicity in genome-wide association studies. *Nature Genetics* 2015; **47**(3): 291-295.
- 9. Peyrot WJ, Price AL. Identifying loci with different allele frequencies among cases of eight psychiatric disorders using CC-GWAS. *Nature Genetics* 2021; **53**(4): 445-454.
- 10. Lee SH, Wray NR, Goddard ME, Visscher PM. Estimating missing heritability for disease from genome-wide association studies. *American journal of human genetics* 2011; **88**(3): 294-305.
- Yap CX, Sidorenko J, Marioni RE, Yengo L, Wray NR, Visscher PM. Misestimation of heritability and prediction accuracy of male-pattern baldness. *Nat Commun* 2018; 9(1): 2537.
- 12. Bycroft C, Freeman C, Petkova D, Band G, Elliott LT, Sharp K *et al.* The UK Biobank resource with deep phenotyping and genomic data. *Nature* 2018; **562**(7726): 203-209.

- 13. Ning Z, Pawitan Y, Shen X. High-definition likelihood inference of genetic correlations across human complex traits. *Nature Genetics* 2020; **52**(8): 859-864.
- 14. Bulik-Sullivan B, Finucane HK, Anttila V, Gusev A, Day FR, Loh P-R *et al.* An atlas of genetic correlations across human diseases and traits. *Nature Genetics* 2015; **47**(11): 1236-1241.
- 15. Glanville KP, Coleman JRI, Howard DM, Pain O, Hanscombe KB, Jermy B *et al.* Multiple measures of depression to enhance validity of Major Depressive Disorder in the UK Biobank. *medRxiv* 2020: 2020.2009.2018.20196451.
- 16. Badini I, Coleman JRI, Hagenaars SP, Hotopf M, Breen G, Lewis CM *et al.* Depression with atypical neurovegetative symptoms shares genetic predisposition with immunometabolic traits and alcohol consumption. *Psychol Med* 2020: 1-11.
- Milaneschi Y, Lamers F, Peyrot WJ, Abdellaoui A, Willemsen G, Hottenga JJ *et al.* Polygenic dissection of major depression clinical heterogeneity. *Mol Psychiatry* 2016; 21(4): 516-522.
- 18. Milaneschi Y, Lamers F, Peyrot WJ, Baune BT, Breen G, Dehghan A *et al.* Genetic Association of Major Depression With Atypical Features and Obesity-Related Immunometabolic Dysregulations. *JAMA Psychiatry* 2017; **74**(12): 1214-1225.
- 19. Fernandez-Pujals AM, Adams MJ, Thomson P, McKechanie AG, Blackwood DHR, Smith BH *et al.* Epidemiology and Heritability of Major Depressive Disorder, Stratified by Age of Onset, Sex, and Illness Course in Generation Scotland: Scottish Family Health Study (GS:SFHS). *PloS one* 2015; **10**(11): e0142197-e0142197.
- 20. Cai N, Bigdeli TB, Kretzschmar W, Li Y, Liang J, Song L *et al.* Sparse whole-genome sequencing identifies two loci for major depressive disorder. *Nature* 2015; **523**(7562): 588-591.
- 21. Viktorin A, Meltzer-Brody S, Kuja-Halkola R, Sullivan PF, Landén M, Lichtenstein P *et al.* Heritability of Perinatal Depression and Genetic Overlap With Nonperinatal Depression. *Am J Psychiatry* 2016; **173**(2): 158-165.
- 22. Coleman JRI, Peyrot WJ, Purves KL, Davis KAS, Rayner C, Choi SW *et al.* Genomewide gene-environment analyses of major depressive disorder and reported lifetime traumatic experiences in UK Biobank. *Molecular psychiatry* 2020; **25**(7): 1430-1446.
- 23. Peterson RE, Cai N, Dahl AW, Bigdeli TB, Edwards AC, Webb BT *et al.* Molecular Genetic Analysis Subdivided by Adversity Exposure Suggests Etiologic Heterogeneity in Major Depression. *The American journal of psychiatry* 2018; **175**(6): 545-554.
- 24. Hall LS, Adams MJ, Arnau-Soler A, Clarke TK, Howard DM, Zeng Y *et al.* Genomewide meta-analyses of stratified depression in Generation Scotland and UK Biobank. *Transl Psychiatry* 2018; **8**(1): 9.

- 25. Kendler KS, Ohlsson H, Lichtenstein P, Sundquist J, Sundquist K. The Genetic Epidemiology of Treated Major Depression in Sweden. *American Journal of Psychiatry* 2018; **175**(11): 1137-1144.
- 26. Davis KAS, Cullen B, Adams M, Brailean A, Breen G, Coleman JRI *et al.* Indicators of mental disorders in UK Biobank-A comparison of approaches. *Int J Methods Psychiatr Res* 2019; **28**(3): e1796-e1796.
- 27. Howard DM, Adams MJ, Clarke T-K, Hafferty JD, Gibson J, Shirali M *et al.* Genomewide meta-analysis of depression identifies 102 independent variants and highlights the importance of the prefrontal brain regions. *Nature Neuroscience* 2019; **22**(3): 343-352.
- 28. Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, Reich D. Principal components analysis corrects for stratification in genome-wide association studies. *Nat Genet* 2006; **38**(8): 904-909.